KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Non-Current Assets for 18 consecutive years, with $910.2 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 3.73% year-over-year to $910.2 million; the TTM value through Mar 2026 reached $3.6 billion, up 1.97%, while the annual FY2025 figure was $915.7 million, 3.07% down from the prior year.
  • Non-Current Assets hit $910.2 million in Q1 2026 for Alnylam Pharmaceuticals, down from $915.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $945.6 million in Q1 2025 and bottomed at $835.8 million in Q1 2024.
  • Average Non-Current Assets over 5 years is $875.9 million, with a median of $854.1 million recorded in 2022.
  • Year-over-year, Non-Current Assets decreased 4.73% in 2024 and then increased 13.13% in 2025.
  • Alnylam Pharmaceuticals' Non-Current Assets stood at $854.1 million in 2022, then fell by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then fell by 3.07% to $915.7 million in 2025, then decreased by 0.59% to $910.2 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $910.2 million, $915.7 million, and $898.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.